Pfizer and Ionis Pharmaceuticals announced that the former is abandoning the vupanorsen program for cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG), or high triglycerides. Pfizer was leading the program.
Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).